A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands

被引：1

作者：

Michels, Renee E. ^{[1
]}

Peters, Michel L. ^{[1
]}

Schiffers, Krijn Mh ^{[2
,3
]}

Bouma, Paul A. ^{[4
]}

Hengstman, Gerald I. D. ^{[5
]}

van Munster, Caspar E. P. ^{[6
]}

Zeinstra, Esther ^{[7
]}

De Voer, Gert ^{[2
,3
]}

Krol, Marieke ^{[1
]}

机构：

[1] IQVIA, Dept Real World & Analyt Solut, Herikerbergweg 314, NL-1101 CT Amsterdam, Netherlands

[2] Merck BV, Darmstadt, Germany

[3] Tupolevlaan 61, NL-1119 NW Schiphol Rijk, Netherlands

[4] Tergooi Ziekenhuis, Dept Neurol, van Riebeeckweg 212, NL-1213 XZ Hilversum, Netherlands

[5] Catharina Hosp, Dept Neurol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands

[6] Amphia Ziekenhuis, Dept Neurol, Molengracht 21, NL-4818 CK Breda, Netherlands

[7] Isala, Dept Neurol, Hoogeveenseweg 38, NL-7943 KA Meppel, Netherlands

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 10卷 / 02期

关键词：

Delphi panel; disease modifying therapy; multiple sclerosis; reimbursement; relapsing remitting multiple sclerosis; the Netherlands; treatment pathway; CELLS; MS;

D O I：

10.2217/cer-2020-0140

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To gain insight into current treatment and barriers to optimal treatment for high disease activity relapsing remitting multiple sclerosis (MS) in the Netherlands. Materials & methods: A two-round Delphi panel using an online questionnaire was conducted. Seven MS neurologists from diverse locations in the Netherlands were invited to participate. Result: Out of the seven MS neurologists, five completed both questionnaire rounds. Conclusion: Effectiveness and side effects along with patient's lesion load were the most important factors for choosing a disease modifying therapy (DMTs). Respondents felt restricted to optimally treat their patients due to reimbursement restrictions for certain disease modifying therapies, although agreed that satisfactory treatment options are currently available. The answers show consensus between the participating MS neurologists with high certainty of answers.

引用

页码：93 / 100

页数：8

共 16 条

[1] Stability of response characteristics of a Delphi panel: Application of bootstrap data expansion
Akins R.B.
Tolson H.
Cole B.R.
[J]. BMC Medical Research Methodology, 5 (1)
[2] Avella J.R., 2016, International Journal of Doctoral Studies, V11, P305, DOI [DOI 10.28945/3561, 10.28945/3561]
[3] The role of CD4 T cells in the pathogenesis of multiple sclerosis
Chitnis, Tanuja
[J]. NEUROBIOLOGY OF MULTIPLE SCLEROSIS, 2007, 79 : 43 - 72
[4] European medicines agency, 2011, GIL SUMM PROD CHAR
[5] European medicines agency, 2006, TYS SUMM PROD CHAR
[6] European medicines agency, 2017, MAV SUMM PROD CHAR
[7] B cells and multiple sclerosis
Franciotta, Diego
Salvetti, Marco
Lolli, Francesco
Serafini, Barbara
Aloisi, Francesca
[J]. LANCET NEUROLOGY, 2008, 7 (09) : 852 - 858
[8] Iqbal S, 2009, PSYCHOLOGIST, V22, P598
[9] Kleinschnitz C., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P35
[10] Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling
Kremer, Ingrid E. H.
Evers, Silvia M. A. A.
Jongen, Peter J.
Hiligsmann, Mickael
[J]. HEALTH EXPECTATIONS, 2018, 21 (01) : 171 - 180

← 1 2 →